THIAMINE DICETYLSULFATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H34O4S.C16H33O4S.C12H17N4OS
Molecular Weight	909.354
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(CCO)SC=[N+]1CC2=CN=C(C)N=C2N.CCCCCCCCCCCCCCCCOS(O)(=O)=O.CCCCCCCCCCCCCCCCOS([O-])(=O)=O

InChI

InChIKey=HVIVKYLMXRWCDK-UHFFFAOYSA-M

InChI=1S/2C16H34O4S.C12H17N4OS/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-21(17,18)19;1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13/h2*2-16H2,1H3,(H,17,18,19);5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15)/q;;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C12H16N4OS
Molecular Weight	264.347
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H34O4S
Molecular Weight	322.504
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/008809s066lbl.pdf

Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thiamin pyrophosphokinase 1 11 Target ID: Q9H3S4 Gene ID: 27010.0 Gene Symbol: TPK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223	Substrate 661
carbohydrate metabolic process 11 Target ID: GO:0005975 Sources: https://www.trc-canada.com/product-detail/?CatNum=T344185	Modulator 846
Oxidative Stress 162 Target ID: WP408 Sources: https://www.bocsci.com/thiamine-cas-70-16-6-item-41803.html	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Thiamine deficiency 13 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/008809s066lbl.pdf	Preventing		Approved 8583	M.V.I.-12 Approved Use M.V.I.-12 Unit Vial, is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition. Launch Date 1953

C_max

Value	Dose	Analyte	Population
40 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
39 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
95 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
113 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
386 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
397 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
214 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
177 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
623 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
612 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2046 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2059 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
3.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	THIAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
500 mg single, intravenous Highest studied dose Dose: 500 mg Route: intravenous Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31932197/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/31932197/	Sources: https://pubmed.ncbi.nlm.nih.gov/31932197/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 779 OCTN2 71	OCT1 393	CYP4B1 11

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP4B1 12	inducer 1966 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000059438, https://pubmed.ncbi.nlm.nih.gov/15328374/	yes	THIAMINE 11
OCT2 782	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00152	yes	THIAMINE 11
OCTN2 71	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00152	yes	THIAMINE 11

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OCT1 393	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00152	yes	THIAMINE 11

Sourcing

Vendor/Aggregator	ID	URL
Aurora Fine Chemicals LLC	K04.000.720	http://online.aurorafinechemicals.com/info?ID=K04.000.720
BLD Pharm	BD153807	http://www.bldpharm.com/products/70-16-6.html
ChemMol	49416419	http://www.chemmol.com/chemmol/49416419.html
ChemMol	49416566	http://www.chemmol.com/chemmol/49416566.html
Chemspace	CSSS00160641068	https://chem-space.com/CSSS00160641068
eNovation Chemicals	D535901	https://www.enovationchem.com/ProductDetails.asp?ProductID=D535901
iChemical	EBD3681937	http://www.ichemical.com/products/70-16-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-2198445125	https://mcule.com/MCULE-2198445125/
MolPort	MolPort-001-920-086	https://www.molport.com/shop/molecule-link/MolPort-001-920-086
Smolecule	S598516	https://www.smolecule.com/products/s598516
THE BioTek	bt-295268	https://www.thebiotek.com/product/others/bt-295268

PubMed

Title	Date	PubMed
Thiamine for Alzheimer's disease.	2001	11405995
Severe metabolic acidosis and heart failure due to thiamine deficiency.	2001 Apr	11369178
Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro.	2001 Apr	11275553
Evidence for non-enzymatic glycosylation in Escherichia coli.	2001 Feb	11251824
In vivo and in vitro proton NMR spectroscopic studies of thiamine-deficient rat brains.	2001 Feb	11169820
Glucose induced IEG expression in the thiamin-deficient rat brain.	2001 Feb 16	11172768
Cresol red thallium acetate sucrose inulin (CTSI) agar for the selective recovery of Carnobacterium spp.	2001 Feb 28	11252499
[Postoperative encephalopathies: thiamine deficiency, an unrecognized etiology].	2001 Jan	11234577
Longitudinal vitamin and homocysteine levels in normal pregnancy.	2001 Jan	11227033
Thiamin treatment and working memory function of alcohol-dependent people: preliminary findings.	2001 Jan	11198705
Phosphorylation of 1-deoxy-D-xylulose by D-xylulokinase of Escherichia coli.	2001 Jan	11168365
Molecular cloning of human thiamin pyrophosphokinase.	2001 Jan 26	11342117
Marginal vitamin and mineral intake of Costa Rican adolescents.	2001 Jan-Feb	11282184
Effects of glucose, vitamins, and DO concentrations on pyruvate fermentation using Torulopsis glabrata IFO 0005 with metabolic flux analysis.	2001 Jan-Feb	11170481
Use of vitamin supplements and cataract: the Blue Mountains Eye Study.	2001 Jul	11438049
Sulphoacetaldehyde sulpho-lyase (EC 4.4.1.12) from Desulfonispora thiosulfatigenes: purification, properties and primary sequence.	2001 Jul 15	11439112
No association between DLST gene and Alzheimer's disease or Wernicke-Korsakoff syndrome.	2001 Jul-Aug	11445257
The crystal structure of yeast thiamin pyrophosphokinase.	2001 Jun	11435118
Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic.	2001 Jun	11430779
Nutritional status in elderly female hip fracture patients: comparison with an age-matched home living group attending day centres.	2001 Jun	11430778
Wernicke's encephalopathy in patients with hyperemesis gravidarum.	2001 Mar	11405565
The genes for anabolic 2-oxoglutarate: ferredoxin oxidoreductase from Hydrogenobacter thermophilus TK-6.	2001 Mar 30	11401501
[Metabolic characteristics of the Yarrowia lipolytica strain producing alpha-ketoglutaric and citric acids from ethanol and the effect of [NH4+] and [O2] on yeast respiration and biosynthesis].	2001 Mar-Apr	11386051
[Other drugs administered with TPN solution].	2001 May	11439537
[Metabolic acidosis induced by TPN].	2001 May	11439535
[Solutions for the hyperalimentation].	2001 May	11439519
The application of capillary electrophoresis to the analysis of vitamins in food and beverages.	2001 May	11386658
Pharmacotherapy of mental illness--a historical analysis.	2001 May	11383974
Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias.	2001 May	11383938
A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome.	2001 May	11380424
Early recognition of acute cardiovascular beriberi by interpretation of hemodynamics.	2001 May	11377164
Stability of thiamine and vitamins E and A during storage of enteral feeding formula.	2001 May	11368595
Examination of donor substrate conversion in yeast transketolase.	2001 May 11	11278369
The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA.	2001 Sep 7	11443125

Patents

Sample Use Guides

In Vivo Use Guide

The starting dose (as a component of M.V.I.–12) is one 10 mL daily dose added directly to an intravenous fluid.

Route of Administration: Intravenous

In Vitro Use Guide

Human Caco-2 cells were incubated (37 Celsius) in Krebs-Ringer buffer (pH 7.4) for different periods of time in the presence of 0.1 uM and 10 uM thiamine. The uptake study demonstrated that thiamine is transported across the cell membrane with Michaelis-Menten constant of 3.18 uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:55:03 GMT 2025` Edited by `admin` on `Mon Mar 31 17:55:03 GMT 2025`
Record UNII	25Z6V0JJ9I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

THIAMINE DICETYLSULFATE

Common Name

English

THIAZOLIUM, 3-((4-AMINO-2-METHYL-5-PYRIMIDINYL)METHYL)-5-(2-HYDROXYETHYL)-4-METHYL-, HEXADECYL SULFATE, HEXADECYL SULFATE (1:1:1)

Preferred Name

English

VITAMIN B1 DICETYLSUFATE

Common Name

English

Code System Code Type Description

FDA UNII

25Z6V0JJ9I

Created by admin on Mon Mar 31 17:55:03 GMT 2025 , Edited by admin on Mon Mar 31 17:55:03 GMT 2025

PRIMARY

PUBCHEM

71587132

Created by admin on Mon Mar 31 17:55:03 GMT 2025 , Edited by admin on Mon Mar 31 17:55:03 GMT 2025

PRIMARY

CAS

35860-05-0

Created by admin on Mon Mar 31 17:55:03 GMT 2025 , Edited by admin on Mon Mar 31 17:55:03 GMT 2025

PRIMARY

EPA CompTox

DTXSID90189414

Created by admin on Mon Mar 31 17:55:03 GMT 2025 , Edited by admin on Mon Mar 31 17:55:03 GMT 2025

PRIMARY

Related Record Type Details


					4ABT0J945J

THIAMINE ION

PARENT -> SALT/SOLVATE

Related Record Type Details


					4ABT0J945J

THIAMINE ION

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/008809s066lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/008809s066lbl.pdf

C_max

T_1/2

Drug as perpetrator